VARIATIONS OF SERUM SIALIC ACID LEVEL IN LIVER CIRRHOSIS

Saatea Arif, Najeeb -ul- Haq, Ruhila Hanif, A. Sattar Khan, Jamil -ur- Rehman, Taufeeq Ahmed Mufti

Abstract


Background: Cirrhosis liver claims many lives in our country. However early diagnosis carries
good prognosis and prevents complications. Estimation of serum sialic acid level may be helpful
in the diagnosis of liver cirrhosis and following the dynamics of the disease especially during
treatment and follow up to see the prognosis. Methods: Sialic acid level of 82 confirmed liver
cirrhosis patients of age between 18-60 years and admitted in Khyber Teaching Hospital Peshawar
was determined and compared with 40 normal controls. The patients were studied in three groups
according to the stage of the disease, i.e. the patients in early stages, in advancing stage, and those
in terminal stage of liver cirrhosis. Sialic acid level was determined on HPLC (Hitachi) with D-
2500 chromatographer. Result: Significantly high levels of sialic acid were recorded in patients as
compared to controls. It was normal in early stage of liver cirrhosis (667±8.06nmol/ml), markedly
increased in advancing cirrhosis (952±3.29nmol/ml) (P<0.05) and very high levels were observed
in terminal stage (1058±7.50nmol/ml). Conclusion: Serum Sialic acid level was high in advancing
and terminal stages of disease as compared to early stage and controls that showed normal levels.
Key words: N-Acetyle Neuraminic Acid (NANA), Sialic acid of glycoproteins, Cirrhosis liver.

Full Text:

PDF

References


Martinz J, Palascak JE, Kwasniak D. Abnormal sialic acid

content of dysfibrinogenemia associated with liver disease. J

Clin Investigation 1978;61:535-8.

Oliver TK, Riidiger H, Michael P, Carolin S . Biochemical

engineering of the N-acyl side chain of Sialic acid: biological

implications. Glycobiology 2001;11(2):11-8.

Hangloo VK, Kaul I, Zargar HU. Serum Sialic acid levels in

healthy individuals. J Postgrad Med 1990;36:140-2.

Lindberg G, Iso H, Rastam L, Lundblad A, Folsom AR.

Serum Sialic Acid and its correlates in community samples

from Akita, Japan and Minnaepolis. USA. Int J Epidemiol

;26(1):58-63.

Okude M, Yamanaka A, Akihama S. The effects of pH on

the generation of turbidity and elasticity associated with

fibrinogen fibrin conversion by thrombin are remarkably

influenced by sialic acid in fibrinogen. Bio-pharm-Bull

;18(2):203-7.

Okude M, Yamanka A, Moriomoto Y, Akihama S. Sialic

acid in fibrinogen. Effects of Sialic acid on fibrinogen-fibrin

conversion by thrombin and properties of asialofibrin clot.

Biol-Pharm-Bull 1993: 16(5) : 448-52.

O’Kennedy R, Berns G, Moran E, Smyth H, Carroll K,

Thornes RD etal. A critical analysis of the use of sialic acid

determination in the diagnosis of malignancy. Cancer Lett

;58(1-2):91-100.

Matsuzaki S, Itakura M, Iwamura K, Kamiguchi H. Serum

Sialic acid levels in liver cirrhosis and liver cancer. NipponShoka-Kibyo-Gakkari-Zasshi 1981;78(12):2395-401.

Hoon DBS, Ngz Sk, Ramshaw IA. Analysis of mammary

tumour cell metastasis and release of bound N-acetyl

neuraminic acid. Br J Cancer 1985;51:775-881.

Palascak JE, Martinz J. Dysfibrinogenemia associated with

liver diseases. J-clin-Invest 1977;60(1):89-95.

Hangvoranuntakul P. Human uptake and incorporation of an

immunogenic non human dietary SA. Proc Natl Acad Sci

USA 2003;14:100(21):12045-50.

Narvaiza MJ, Fernandez J, Cuesta B, Paramo JA, Rocha E.

Role of Sialic acid in acquired dysfibrinogenemia associated

with liver cirrhosis. Ricerca in clinica e in laboratorio

;16(4):563-8.

Carlson J. α antitrypsin and other acute phase reactants in

liver-disease. Acta Med Scand 1980; 207:79.

J Ayub Med Coll Abbottabad 2005;17(3)

Kaniak J, Mejbaum KBW, Jelewska KZ, Kudreweiz HZ,

Kowal GZ. Sialic acid contents of glyproteins and

seromuciod in liver diseases. Polish Medical Journal

;1(5):1076-81.

Luchansky SJ, Goon S, Bertozzi CR. Expanding the diversity

of unnatural cell surface S acids. Chem bioch 2004;5(3):371-

Kongtawelert P, Tangkijvanich P, ong-chi S, Poovorawan Y.

Role of SA in differentiating cholangiocarcinoma from

hepatocellular carcinoma. World Gastroenterol

;9(10):2178-81.


Refbacks

  • There are currently no refbacks.


Contact Number: +92-992-382571

email: [jamc] [@] [ayubmed.edu.pk]